Medication adherence with disease modifying treatments for multiple sclerosis among US employees

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 633-640

  Kleinman, Nathan L ^a   Beren, Ian A ^a   Rajagopalan, Krithika ^b   Brook, Richard A ^c  

^a Human Capital Management Services   (United States)

^b BIOGEN   (United States)

^c JeSTARx Group   (United States)

Author keywords

Adherence; Compliance; DMT therapy; Interferons; Multiple sclerosis; Persistence

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; DATA BASE; DRUG DOSE TITRATION; EMPLOYEE; FEMALE; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; ADULT; DRUG UTILIZATION; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE CLAIM REVIEW; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; PEPTIDES; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 78650053312     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.527588     Document Type: Article

References (35)

1. Porter R & Kaplan J, editors. Merck Manual online: Multiple Sclerosis. Available at http://www.merck.com/mmpe/sec16/ch222/ch222b.html. Accessed October 21, 2009
2. Multiple Sclerosis International Federation: Epidemiology. Available at http:// www.msif.org/en/. Accessed October 21, 2009
3. Joy JE, Johnston RB, eds. Multiple Sclerosis: Current Status and Strategies for the Future Committee on Multiple Sclerosis. Washington, DC: National Academy Press, 2004. Available in part at: Http://books.nap.edu/ execsumm-pdf/10031.pdf. Accessed March 3, 2008
4. Multiple Sclerosis Foundation: Epidemiology. Available at http://www.msfocus. org/who-gets-multiple-sclerosis.aspx. Accessed October 21, 2009
5. Miller JR. The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm 2004;10(Suppl B):S4-11
6. Avonex PI. Available at http://www.fda.gov/downloads/Drugs/Development ApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm086060.pdf. Accessed May 26 2010
7. Betaseron PI. Available at http://berlex.bayerhealthcare.com/html/ products/ pi/Betaseron-PI.pdf?WT.mc-id=www.berlex.com. Accessed September 23 2009
8. Rebif PI. Available at http://www.mslifelines.com/-assets/pdf/Rebif-PI. pdf?source=external. Accessed September 23 2009
9. Copaxone PI. Available at http://www.copaxone.com/pdf/ prescribinginformation. pdf. Accessed September 23 2009
10. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008;10:225. Epub 2008 September 30
11. Cohen BA. Adherence to disease-modifying therapy for multiple sclerosis. Int J MS Care 2006;Suppl:32-37
12. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
13. Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50:105-116
14. Choo P, Rand C, Inui T, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to anti-hypertensive therapy. Med Care 1999;37:846-857
15. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 2008;255(Suppl 6):87-92
16. Lafata JE, Cerghet M, Dobie E, et al. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. J Am Pharm Assoc (2003). 2008;48:752-757
17. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59: 131-135. Epub 2007 November 30
18. Ross AP. Tolerability, adherence, and patient outcomes. Neurology 2008; 71:S21-23
19. Beer K, Muller M, Hew-Winzeler A, et al. An evaluation of adverse skin reactions in patients with multiple sclerosis. Mult Scler 2009;15:S238-239
20. Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663-674
21. Fraser C, Morgante L, Hadjimichael O, et al. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004;36:120-129
22. Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-309
23. Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of theβ-interferons prescribed for MS. Neurology 2003;61:551-554
24. Daugherty KK, Butler JS, Mattingly M, et al. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2003;45:371-375
25. Turner AP, Williams RM, Sloan AP, et al. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol 2009; 54:116-121
26. The Health Insurance Portability and Accountability Act (HIPAA) Fact Sheet. U.S. Department of Labor, Employee Benefits Security Administration, December 2004. Available at http://www.dol.gov/ebsa/newsroom/fshipaa. html. Accessed February 29 2008
27. Brook RA, Rajagopalan K, Kleinman NL, et al. Absenteeism and health benefit costs among employees with multiple sclerosis. Curr Med Res Opin 2009; 25:1469-1476
28. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383
29. Devonshire V, Cassidy DD, Popelar L. Adherence to disease-modifying therapy- recognizing barriers and offering solutions: A roundtable discussion. In: Ross AP, Editor in MS Counseling Points. Ridgewood, NJ: Delaware Media Group, LLC, 2007:3:1-12. Available at http://www.iomsn.org/pdf/ CPMS0702.final.pdf. Accessed May 26 2010
30. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15:e22-33
31. Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686-1694
32. Minden SL, Frankel D, Hadden L, et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006;12:24-38
33. Vogenberg FR, Holland JP, Liebeskind D. Employer benefit design considerations for the era of biotech drugs. J Occup Environ Med 2007;49:626-632
34. Stephenson JJ, Kamat SA, Cai Q, et al. Economic impact of disease-modifying therapies in multiple sclerosis patients in a managed care setting. Value Health 2009;12:A192
35. SAS Institute Inc., SAS/STAT 9.2 User's Guide, Cary, NC: SAS Institute Inc., 2008